Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

141 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Switching from high-efficacy lipid-lowering therapies to simvastatin and low-density lipoprotein cholesterol goal attainment in coronary heart disease/coronary heart disease-equivalent patients.
Tunceli K, Sajjan SG, Ramey DR, Neff DR, Tershakovec AM, Hu XH, Tomassini JE, Foody JM. Tunceli K, et al. Among authors: tershakovec am. J Clin Lipidol. 2010 Nov-Dec;4(6):491-500. doi: 10.1016/j.jacl.2010.10.004. Epub 2010 Oct 13. J Clin Lipidol. 2010. PMID: 21122696
Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.
Foody JM, Toth PP, Tomassini JE, Sajjan S, Ramey DR, Neff D, Tershakovec AM, Hu H, Tunceli K. Foody JM, et al. Among authors: tershakovec am. Vasc Health Risk Manag. 2013;9:719-27. doi: 10.2147/VHRM.S49840. Epub 2013 Nov 15. Vasc Health Risk Manag. 2013. PMID: 24265554 Free PMC article.
Real-world data to assess changes in low-density lipoprotein cholesterol and predicted cardiovascular risk after ezetimibe discontinuation post reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial.
Bays HE, Patel MD, Mavros P, Ramey DR, Tomassini JE, Tershakovec AM, Baxter CA. Bays HE, et al. Among authors: tershakovec am. J Clin Lipidol. 2017 Jul-Aug;11(4):929-937. doi: 10.1016/j.jacl.2017.04.121. Epub 2017 May 8. J Clin Lipidol. 2017. PMID: 28647412
Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction.
Toth PP, Ballantyne CM, Davidson MH, Tomassini JE, Ramey DR, Neff D, Tershakovec AM, Hu XH, Tunceli K. Toth PP, et al. Among authors: tershakovec am. J Clin Lipidol. 2012 Mar-Apr;6(2):180-91. doi: 10.1016/j.jacl.2011.11.007. Epub 2011 Dec 7. J Clin Lipidol. 2012. PMID: 22385552
Changing characteristics of statin-related cIMT trials from 1988 to 2006.
Davidson MH, Tomassini JE, Jensen E, Neff D, Polis AB, Tershakovec AM. Davidson MH, et al. Among authors: tershakovec am. Atherosclerosis. 2016 Mar;246:121-9. doi: 10.1016/j.atherosclerosis.2015.11.023. Epub 2015 Nov 25. Atherosclerosis. 2016. PMID: 26773471
141 results